Accessibility Menu
Wave Life Sciences Stock Quote

Wave Life Sciences (NASDAQ: WVE)

$7.17
(-8.7%)
-0.68
Price as of October 22, 2025, 12:53 p.m. ET

KEY DATA POINTS

Current Price
$7.17
Daily Change
(-8.7%) $0.68
Day's Range
$7.13 - $7.84
Previous Close
$7.85
Open
$7.82
Beta
1.37
Volume
57,325
Average Volume
2,007,158
Market Cap
1.2B
Market Cap / Employee
$7.85M
52wk Range
$5.28 - $16.74
Revenue
-
Gross Margin
0.91%
Dividend Yield
N/A
EPS
-$0.89
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Wave Life Sciences Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
WVE-48.05%-5.54%-1.13%-51%
S&P+15.06%+95.03%+14.29%+225%

Wave Life Sciences Company Info

Wave Life Sciences Ltd. is a clinical-stage genetic medicines company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, optimization, and production of novel stereopure oligonucleotides. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$8.70M-55.8%
Gross Profit$6.50M-62.9%
Gross Margin74.76%-14.2%
Market Cap$1.01B65.5%
Market Cap / Employee$3.51M0.0%
Employees2887.5%
Net Income-$50.47M-53.3%
EBITDA-$50.56M-54.0%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$208.48M35.4%
Accounts Receivable$1.62M25.3%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$13.58M-37.5%
Short Term Debt$8.14M13.6%

Ratios

Q2 2025YOY Change
Return On Assets-56.32%-22.7%
Return On Invested Capital547.48%30.1%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$48.31M-77.4%
Operating Free Cash Flow-$48.00M-76.6%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book8.5912.965.905.83-75.75%
Price to Sales20.2819.6812.5111.3593.98%
Price to Tangible Book Value8.5912.965.905.83-75.75%
Enterprise Value to EBITDA-13.1374.13-23.12-17.548.83%
Return on Equity-243.8%-73.2%-105.5%-171.4%-91.11%
Total Debt$27.17M$25.40M$23.60M$21.71M-24.81%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.